Johnson and JohnsonThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2 3 4 5 6 7 8 9 10 11

524 records returned

Metabolic Effects Significantly Lower With INVEGA® Compared to Olanzapine(Nov 18, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Beerse, Belgium (November 18th 2009)-- New data from a 6-month open label randomised controlled trial show INVEGA® (paliperidone ER) is associated with significantly less metabolic effects compared to oral olanzapine in people with schizophrenia, while demonstrating comparable efficacy.1 (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 18, 2009 Category: Pharmaceuticals Source Type: organizations

National Expressions of Courage Art Contest Unveils Stories of Inspiration(Nov 16, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Raritan, NJ (November 16, 2009 - Epilepsy and seizures affect nearly 3 million Americans of all ages and in 70 percent of new cases, no cause is apparent. Those who live daily with the condition have no way of knowing when the next seizure will occur, how long it will last or where they will be, often experiencing a roller coaster of emotions as they cope with the condition. The wonder behind the diagnosis, the perseverance in managing it, and the support received through family and friends are some examples of the stories told through artwork in the 2009 Expressions of Courage® art contest, a national art competition inv...
Source: Johnson and Johnson - November 16, 2009 Category: Pharmaceuticals Source Type: organizations

DePuy plans to phase out manufacture at Leeds facility(Nov 12, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
November 12, 2009 - Following a detailed review of its global production requirements versus capacity, DePuy intends to phase out manufacturing at its facility in St. Anthony’s Road, Beeston, Leeds, subject to statutory consultation. The company plans to rationalise its product portfolio to focus on lines that best meet the current and emerging needs of surgeons and patients. Several of these product lines are produced at the Leeds facility. ..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 12, 2009 Category: Pharmaceuticals Source Type: organizations

Analysis Underscores Financial Burden of Mental Illness on Criminal Justice and Health Care Systems(Nov 11, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Philadelphia, PA (November 11, 2009) – Results from a large, retrospective analysis of inmates with a serious mental illness (SMI) underscores the financial burden of mental illness on the criminal justice and health and human services (HHS) systems, and may provide useful information to policy makers. The results of the analysis, which evaluated patterns of arrest, utilization of services, and corresponding expenditures among nearly 3,800 inmates in a large urban county of Florida, were presented this week at the 137th (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 11, 2009 Category: Pharmaceuticals Source Type: organizations

Longer Prescribed Replacement Intervals Leads to More Stretching of Frequent Replacement Contact Lenses(Nov 11, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Orlando, FL (November 11, 2009) – Contact lenses prescribed for longer replacement intervals can lead to more extreme over wear (stretching) that could lead to undesirable clinical effects, new research shows..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 11, 2009 Category: Pharmaceuticals Source Type: organizations

Neutrogena Launches Online Holiday Shopping Destination(Nov 9, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Los Angeles, CA (November 9, 2009) – Neutrogena®, the #1 dermatologist recommended skincare brand, today launches Neutrogena Holiday (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 9, 2009 Category: Pharmaceuticals Source Type: organizations

McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL® Arthritis Pain 100 Count with EZ-OPEN CAP(Nov 6, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Fort Washington, PA (November 6, 2009) - In consultation with the U.S. Food and Drug Administration (FDA), McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc., is initiating a voluntary recall of a limited number of product lots of TYLENOL® Arthritis Pain Caplet 100 count bottles, with the distinctive red EZ-OPEN CAP. McNeil is initiating the recall after identifying an uncharacteristic smell or taste associated with these lots that led to a small number of consumers reporting nausea and related symptoms. This recall includes five product lots only (Full list of lot numbers provided below), and does not include any o...
Source: Johnson and Johnson - November 6, 2009 Category: Pharmaceuticals Source Type: organizations

Johnson & Johnson to Participate in Credit Suisse 18th Annual Health Care Conference(Nov 5, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New Brunswick, NJ (November 5, 2009) -- Johnson & Johnson will participate in the Credit Suisse 18th (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 5, 2009 Category: Pharmaceuticals Source Type: organizations

Ortho Clinical Diagnostics Launches First-of-its-kind Remote Monitoring Center(Nov 4, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Paris, France (November 4th, 2009) Ortho Clinical Diagnostics (OCD) today announced the launch of a first-of-its-kind 24-7 central command center in Strasbourg, France, that continuously tracks the condition of clinical laboratory instrument performance. The Remote Monitoring Center in Strasbourg provides unique predictive monitoring services to laboratories throughout Europe and the Asia-Pacific region by continuously detecting and tracking potential instrument problems up to 30 days in advance, before they interrupt the ability of the lab to deliver quality test results..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 4, 2009 Category: Pharmaceuticals Source Type: organizations

Lesser-Known Effects of Smoking Can Play Havoc with Women's Health(Nov 4, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Toronto, Canada (November 4th, 2009)- Many women are aware that smoking can lead to lung cancer, heart disease and premature death. But a recent survey conducted by Angus Reid on behalf of nicotine replacement therapy brands, NICODERM(R) and NICORETTE(R) reveals that the majority of Canadian women who smoke are not necessarily aware of the host of other impacts that smoking can have on their immediate and longer term health..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 4, 2009 Category: Pharmaceuticals Source Type: organizations

CONCERTA® in the Classroom: New Data on Attention in Children With ADH(Nov 4, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
>Las Vegas, NV (November 4th, 2009) -- New findings presented today show that CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) is the only stimulant medication with data that demonstrate a significant treatment effect on attention at one hour and through 12.5 hours in children with Attention Deficit Hyperactivity Disorder (ADHD). ADHD is a common and treatable medical condition characterized by inattention, hyperactivity and impulsivity(1) that is estimated to affect about 5 million children(2) in the United States..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 4, 2009 Category: Pharmaceuticals Source Type: organizations

Johnson & Johnson Announces Restructuring Initiatives for Sustainable Growth (Nov 3, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New Brunswick, NJ (Nov. 3, 2009) – Johnson & Johnson today announced global restructuring initiatives designed to strengthen the company’s position as the world’s leading global health care company. The company is taking steps to prioritize its innovation efforts around the many growth opportunities in health care and to execute aggressively on bringing key new products to market. ..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 3, 2009 Category: Pharmaceuticals Source Type: organizations

More Than 80 Percent of HCV Genotype 1 Treatment-Naive Patients Achieved Sustained Virologic Response With Twice-Daily Telaprevir-Based Regimen(Oct 31, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cork, Ireland (October 31, 2009) –Tibotec announced today results of a new study (VX950-C208), which showed that sustained virologic response (SVR) was achieved in more than 80 percent of treatment-naïve patients with chronic genotype 1 hepatitis C virus (HCV) who took telaprevir, administered either every 8 hours or every 12 hours, in combination with standard of care. Telaprevir, an investigational STAT-C (S (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 31, 2009 Category: Pharmaceuticals Source Type: organizations

New Studies Demonstrate Benefits of Minimally Invasive Hysterectomy and Colectomy When Compared To Open Surgery(Oct 30, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cincinnati, OH (October 26, 2009)– Ethicon Endo-Surgery today announced results from two newly published studies that demonstrate a minimally invasive approach in three common procedures resulted in a reduced rate of complications and lower overall cost of care, including a difference of more than $15,000 on average for minimally invasive colectomies, when compared to open surgery. One study compared two types of minimally invasive hysterectomy procedures to open abdominal hysterectomy1 (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 30, 2009 Category: Pharmaceuticals Source Type: organizations

Cordis Initiates Nationwide Recall Of CROSSOVER™ Sheath Introducer(Oct 26, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bridgewater, NJ. (October 23, 2009) – Cordis Corporation announced today a nationwide voluntary recall of all lots of the CROSSOVER™ Sheath Introducer due to complaints about stretching or fracture of the sheath during use. ..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 26, 2009 Category: Pharmaceuticals Source Type: organizations

Xerox Chairman Anne M. Mulcahy Appointed to Johnson & Johnson Board of Directors (Oct 22, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New Brunswick, NJ, (October 22, 2009) -- Anne M. Mulcahy, Chairman of Xerox Corporation (NYSE: XRX), today was appointed to the Board of Directors of Johnson & Johnson (NYSE: JNJ), the world's most broadly based health care products company..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 22, 2009 Category: Pharmaceuticals Source Type: organizations

More than 1 million Americans suffer from IC(Oct 20, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Raritan, NJ (October 20, 2009) – More than one million Americans – most of them women –suffer from a painful and little-known bladder condition called interstitial cystitis (IC). To raise awareness and recognize the ongoing struggles of people living with this painful bladder condition, Ortho Women’s Health & Urology™ announces the second annual Interstitial Cystitis Awareness Week (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 20, 2009 Category: Pharmaceuticals Source Type: organizations

New Study Reveals Link Between Stress Reduction and Increased Fertility(Oct 19, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Skillman, NJ (October 19, 2009) – Women who participated in a stress management program prior to or during their second IVF cycle had a 160 percent greater pregnancy rate than women who did not participate in a program, according to a study presented today at the American Society for Reproductive Medicine’s 65th (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 19, 2009 Category: Pharmaceuticals Source Type: organizations

New Simponi™ Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis (Oct 19, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Philadelphia, PA (October 19, 2009) – New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI™ (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 19, 2009 Category: Pharmaceuticals Source Type: organizations

New Simponi™ Data Show Inhibition of Joint Damage in Patients with Rheumatoid Arthritis and Psoriatic Arthritis(Oct 19, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Philadelphia, PA – October 19, 2009 – Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI™ (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA). Radiographic analyses showed that treatment with SIMPONI resulted in a statistically significant reduction in change from baseline in structural damage as measured using the van der Heijde-Sharp (vdH-S) scoring method, an X-ray measure of changes in joint destruction, inc...
Source: Johnson and Johnson - October 19, 2009 Category: Pharmaceuticals Source Type: organizations

Health Canada Endorsed Important Safety Information on INTELENCE* (etravirine)(Oct 19, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Toronto (October 19, 2009) - Tibotec, a division of Janssen-Ortho Inc. ("Tibotec"), in collaboration with Health Canada, would like to inform patients of important safety information regarding severe skin reactions in patients receiving HIV combination therapy including INTELENCE (etravirine) tablets. Reports have included severe allergic reactions sometimes accompanied by liver failure, and one report of death..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 19, 2009 Category: Pharmaceuticals Source Type: organizations

Biosense Webster Receives FDA Clearance For The CARTO® 3 System(Oct 15, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Diamond Bar, CA (October 15, 2009) – (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 15, 2009 Category: Pharmaceuticals Source Type: organizations

Ortho Clinical Diagnostics Receives FDA Approval for First Anti-HIV 1+2 Test for Use on Random Access, Integrated Laboratory Testing System(Oct 15, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Raritan, N.J. (Oct. 14, 2009) - Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems. This is the first HIV diagnostic assay approved for an integrated system in the United States, allowing laboratories to run HIV and other routine tests on a single testing platform and eliminating the need for expensive batch testing of multiple patient samples..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 15, 2009 Category: Pharmaceuticals Source Type: organizations

Johnson & Johnson Reports 2009 Third-Quarter Results:(Oct 13, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New Brunswick, NJ (October 13, 2009) – Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 13, 2009 Category: Pharmaceuticals Source Type: organizations

Ethicon Endo-Surgery Introduces Innovation-Enabling Solutions Across the Spectrum of Surgery at ACS(Oct 12, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Chicago, IL (October 12, 2009) -- Ethicon Endo-Surgery introduced several novel surgical solutions at the 95th Annual Clinical Congress of the American College of Surgeons, highlighting how the company is enabling innovation through collaboration across the continuum of surgical techniques and options. A surgeon-only online community, first-of-its-kind technology to improve surgical visualization, a new Access System for single-site laparoscopy (SSL), and an articulating endoscopic linear cutter are among the latest additions to the Ethicon Endo-Surgery portfolio of solutions that respond to surgeon and patient needs..... ...
Source: Johnson and Johnson - October 12, 2009 Category: Pharmaceuticals Source Type: organizations

Ethicon Endo-Surgery Wins Prestigious International Design Award for Innovative Development of HARMONIC FOCUS™(Oct 8, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cincinnati – (October 8, 2009) – Ethicon Endo-Surgery today announced the company won a Gold 2009 International Design Excellence Award (IDEA) for the research and design process used in the development of the HARMONIC FOCUS™ Curved Shear. The company was recognized among thousands of entries for its innovative use of four types of research, including extensive collaboration with surgeons across the globe to identify specific unmet needs in thyroid procedures, which played a critical role in the final product. This award is the latest among several other recent honors Ethicon Endo-Surgery has received for products in...
Source: Johnson and Johnson - October 8, 2009 Category: Pharmaceuticals Source Type: organizations

Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Medical Devices & Diagnostics Business (Oct 6, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New Brunswick, NJ (October 6, 2009) - Johnson & Johnson will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Oct. 13, 2009, to discuss third-quarter financial results and review its Medical Devices & Diagnostics business. The meeting will be hosted by Alex Gorsky, Worldwide Chairman, Medical Devices & Diagnostics; Dominic Caruso, Vice President, Finance and Chief Financial Officer; and Louise Mehrotra, Vice President, Investor Relations..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 6, 2009 Category: Pharmaceuticals Source Type: organizations

SIMPONI™ (golimumab) Receives European Approval As Once-Monthly Subcutaneous Anti-Tnf For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis With Novel Smartject™ Autoinjector(Oct 6, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Horsham, PA and Kenilworth, NJ, (October 6, 2009) – Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP) announced today that the European Commission has approved SIMPONI™ (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderate-to-severe, active rheumatoid arthritis (RA), active and progressive psoriatic arthritis (PsA) and severe, active ankylosing spondylitis (AS). ..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 6, 2009 Category: Pharmaceuticals Source Type: organizations

Veridex’s Cellsearch® Circulating Tumor Cell Test Wins Prestigious Prix Galien Award for Best Medical Technology(Oct 1, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Raritan, N.J., (Oct. 1, 2009) – Veridex, LLC announced today that the CellSearch® Circulating Tumor Cell (CTC) Test was honored with the first-ever Prix Galien USA 2009 Award for Best Medical Technology. ..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 1, 2009 Category: Pharmaceuticals Source Type: organizations

McNeil Consumer Healthcare, a division of Johnson & Johnson Inc. (Canada) announces a voluntary nationwide recall of Adult TYLENOL® Cold Rapid Release Daytime/Nighttime Combination package due to print error(Sep 30, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Mar, ON, (September. 29, 2009) (Canada NewsWire via COMTEX News Network) -- McNeil Consumer Healthcare, a Division of Johnson & Johnson Inc. (Canada) is voluntarily recalling units of Adult TYLENOL® Cold Rapid Release Daytime/Nighttime Combination 18 count packages, an over-the-counter cold product, due to a print error in the French copy of the Nighttime product foil blister backing. The company is taking this action in consultation with Health Canada..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 30, 2009 Category: Pharmaceuticals Source Type: organizations

Cordis Corporation Announces Agreement with Boston Scientific to Settle Selected Stent Litigation Cases(Sep 29, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bridgewater, NJ -- September 29, 2009 – Cordis Corporation (“Cordis”) announced today that it has reached an agreement with Boston Scientific (“Boston”) resolving its Palmaz infringement suit relating to Boston’s NIR stent, settling several other cardiology-related cases relating to patents in the Ding, Kastenhofer, Palmaz, and Fontirroche patent families, and exchanging paid-up licenses for certain intellectual properties. In addition, Boston will pay Cordis Corporation $716.3 million on October 1. Johnson & Johnson expects to record the majority of this payment as a special item during the fourth qu...
Source: Johnson and Johnson - September 29, 2009 Category: Pharmaceuticals Source Type: organizations

AMBI® Skincare Announces Winners of the AMBI® Scholarship in Science & Medicine(Sep 28, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Skillman, NJ (Sept. 28, 2009) AMBI® Skincare proudly announces the five winners of the AMBI® Scholarship in Science & Medicine, a scholarship program designed to recognize, reward and support African American and Hispanic women in fields in which they are currently underrepresented..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 28, 2009 Category: Pharmaceuticals Source Type: organizations

Johnson & Johnson and Crucell Announce Strategic Collaboration to Develop Innovative Products, Including Therapies for Influenza Prevention and Treatment(Sep 28, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New Brunswick, NJ and Leiden, the Netherlands (September 28, 2009) – Johnson & Johnson (NYSE: JNJ) and Crucell, N.V., (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that Johnson & Johnson, through its subsidiary Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Crucell have entered into a strategic collaboration focusing on the discovery, development and commercialization of monoclonal antibodies and vaccines for the treatment and prevention of influenza and other infectious and non-infectious diseases..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 28, 2009 Category: Pharmaceuticals Source Type: organizations

STELARA™ (Ustekinumab) Receives Fda Approval For Treatment Of Moderate To Severe Plaque Psoriasis With Four-Times-A-Year Maintenance Dosing (Sep 25, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Horsham, PA (September 25, 2009) – Centocor Ortho Biotech Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved STELARA™ (ustekinumab) for the treatment of adult patients 18 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. The efficacy and safety of STELARA were evaluated in one of the largest clinical development programs for a biologic medication in the treatment of psoriasis..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 25, 2009 Category: Pharmaceuticals Source Type: organizations

NEVO™ Sirolimus-eluting Coronary Stent Associated with Significantly Less Chest Pain at Six Months than Taxus® Liberte® Stent(Sep 24, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
San Francisco, CA (September 24, 2009) – At six months, patients receiving the NEVO™ Sirolimus-eluting Coronary Stent reported significantly less chest pain (also known as angina) than those receiving the Taxus® Liberte® Stent. Patients also reported improvements in their overall quality of life. These data demonstrate the important benefits of drug-eluting stents in reducing chest pain in patients with coronary artery disease..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 24, 2009 Category: Pharmaceuticals Source Type: organizations

New Clinical Trial Results Show Germ-Killing Action of LISTERINE® Antiseptic Kills Germs in the Mouth Before They Travel To the Bloodstream(Sep 24, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Morris Plains, NJ (September 24, 2009) — The results of a new clinical study demonstrate that the plaque and gingivitis germ-killing action of LISTERINE® Antiseptic significantly reduces the amount of germs that travel from the mouth to the bloodstream in people with mild to moderate gingivitis. These findings are significant, as emerging science suggests that gingivitis, if left untreated and allowed to progress to advanced gum disesase, could contribute to broader health problems such as diabetes, cardiovascular disease, and pneumonia..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 24, 2009 Category: Pharmaceuticals Source Type: organizations

Statewide Partnerships Address Local Nursing Shortage(Sep 23, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Baltimore, MD (September 23, 2009) - As part of its ongoing commitment to help alleviate the nursing shortage in Maryland and across the United States, The Johnson & Johnson Campaign for Nursing’s Future will host the “Promise of Nursing for Maryland” gala on Thursday, September 24 to raise funds to help ease the shortage throughout the region. One hundred percent of the event’s proceeds will support regional nursing school grants, faculty fellowships and student scholarships..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 23, 2009 Category: Pharmaceuticals Source Type: organizations

Janssen-Cilag's STELARA® (Black Triangle Drug) (ustekinumab) Approved by NICE for the Treatment of Moderate to Severe Plaque Psoriasis(Sep 23, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
HIGH WYCOMBE, England (September 23, 2009)-- STELARA (ustekinumab) has today been approved by the National Institute for Health and Clinical Excellence (NICE) as a treatment option for adults with moderate to severe plaque psoriasis,(1) a notoriously difficult-to-treat kin condition for which many patients report feeling dissatisfied and frustrated with existing treatment options.(2..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 23, 2009 Category: Pharmaceuticals Source Type: organizations

ASP Launches 24-Minute EXPRESS Cycle for the STERRAD® 100NX™ System(Sep 21, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Irvine, CA (September 21, 2009) -- Advanced Sterilization Products (ASP) announced today the availability of the STERRAD® 100NX™ System EXPRESS Cycle in the Europe, Middle East and Africa (EMEA) Region. This new, faster cycle is designed for terminal surface sterilization of da Vinci® 3D endoscopes, as well as rigid telescopes, rechargeable batteries and many other devices. The EXPRESS cycle fulfills urgent sterilization needs without the damage associated with other sterilization modalities..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 21, 2009 Category: Pharmaceuticals Source Type: organizations

The Makers Of LISTERINE® And REACH® TOTAL CARE Products Unveil A New Laugh-Out-Loud Book Benefiting The National Children’s Oral Health Foundation®: America's Toothfairy(Sep 17, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Morris Plains, NJ – (September 17, 2009) – The makers of LISTERINE® and REACH® TOTAL CARE introduce an exclusive, limited-edition book titled “36 ½ Reasons to Laugh: A Slice of Life.” This custom book is inspired by funny moments in everyday life – including dating mishaps, office gaps, and family antics – and features a foreword authored by ABC’s Desperate Housewives (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 17, 2009 Category: Pharmaceuticals Source Type: organizations

Johnson & Johnson and Elan Corporation plc Announce Closing of Transaction Related to Alzheimer's Immunotherapy Program and Equity Investment (Sep 17, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New Brunswick, N.J., and Dublin, Ireland, September 17, 2009 – Johnson & Johnson (NYSE: JNJ) and Elan Corporation plc (NYSE: ELN) today announced that JANSSEN Alzheimer Immunotherapy, a newly formed subsidiary of Johnson & Johnson, has completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer’s Immunotherapy Program (AIP). In addition, Johnson & Johnson, through its affiliate, Janssen Pharmaceutical, has invested $885 million in exchange for newly issued American Depositary Receipts (ADRs) of Elan, representing 18.4% of Elan’s outstanding ordinary share...
Source: Johnson and Johnson - September 17, 2009 Category: Pharmaceuticals Source Type: organizations

Resolve to Sweat Smart this Fall with Proper Pain Prevention - and Treatment (Sep 14, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Toronto, Canada (September 14th 2009) The month of September marks more than just the end of summer vacation and back to school. It's also a time for starting new routines and for many Canadians, a time to renew health and lifestyle resolutions including increased physical activity and getting back to the gym. Yet, many of the new and renewed fitness fanatics this fall may not realize that rushing into a new exercise program can result in unnecessary pains, strains and even injury..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 14, 2009 Category: Pharmaceuticals Source Type: organizations

Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL® for the Treatment of Advanced Breast Cancer(Sep 11, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Horsham, Pa., September 10, 2009 – Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection)in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 11, 2009 Category: Pharmaceuticals Source Type: organizations

FDA Issues Complete Response Letter for Trabectedin Combined With DOXIL(Sep 10, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Horsham, PA (September 10, 2009) – Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for trabectedin when administered in combination with DOXIL® (doxorubicin HCI liposome injection)for the treatment of women with relapsed ovarian cancer. The agency has requested additional information, including overall survival data from the company’s ongoing pivotal trial and additional clinical pharmacology studies..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 10, 2009 Category: Pharmaceuticals Source Type: organizations

Pro Quarterback David Garrard Aims to Score Big for Crohn's Disease During the 2009 Football Season(Sep 9, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Horsham, PA (September 9, 2009) – Centocor Ortho Biotech Inc. announced today that the In the Zone for Crohn’s program with David Garrard, quarterback for the Jacksonville Jaguars® will continue this football season to raise awareness and provide funding for Crohn’s disease research, education and support. Building on the success of last year’s program, which raised $170,000 for the Crohn’s & Colitis Foundation of America (CCFA), Centocor Ortho Biotech will again make a donation of $10,000 to the CCFA for each touchdown Garrard scores, passing or rushing, during the 2009 NFL season..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 9, 2009 Category: Pharmaceuticals Source Type: organizations

CONCERTA® (methylphenidate HCI) Launches Mobile Web Experience To Provide Tools and Support for ADHD Awareness (Sep 9, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Titusville, NJ (Sept. 9, 2009) — Attention Deficit Hyperactivity Disorder (ADHD) is estimated to impact up to 20 percent of children1 (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 9, 2009 Category: Pharmaceuticals Source Type: organizations

Depuy Orthopaedics, Inc. And Depuy Mitek, Inc. Launch New Web Site for Primary Care Providers On Chronic Shoulder Pain (Sep 9, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Warsaw, IN (September 9, 2009) – (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 9, 2009 Category: Pharmaceuticals Source Type: organizations

Johnson & Johnson Honors 2009 Recipient of The Dr. Paul Janssen Award for Biomedical Research (Sep 8, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Beerse, Belgium – September 8, 2009 – Johnson & Johnson today honored the career achievements of Axel Ullrich, Ph.D., with the 2009 Dr. Paul Janssen Award for Biomedical Research. Dr. Ullrich received this award for his scientific discoveries that led to innovative new drugs including Herceptin® (trastuzumab),* a personalized medicine therapy, which was the first to target a specific type of breast cancer. Dr. Ullrich also led the development of the first drug created through gene cloning, a recombinant human insulin for treating diabetes which arguably marked the beginning of the biotechnology age. Dr. Ullrich, d...
Source: Johnson and Johnson - September 8, 2009 Category: Pharmaceuticals Source Type: organizations

Johnson & Johnson to Participate in Morgan Stanley Global Healthcare Unplugged Conference(Sep 8, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New Brunswick, NJ (September 8, 2009) -- Johnson & Johnson (NYSE:JNJ) will participate in the Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 15th (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 8, 2009 Category: Pharmaceuticals Source Type: organizations

Ethicon Endo-Surgery Expands REALIZE™ Solution (Sep 8, 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cincinnati, OH (September 8th, 2009) – (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 8, 2009 Category: Pharmaceuticals Source Type: organizations